Clin Lab
-
Pulmonary hamartoma is one of the most common benign tumors of the lung, the symptoms are often atypical, so its diagnosis is not so easy. We presented an elderly man with elevated D-dimer combined persistent acupuncture-like chest pain misdiagnosed as pulmonary embolism finally proved as lung hamartoma with secondary lung infection by bronchoscopy biopsy. ⋯ Elevated D-dimer is not a specific index of pulmonary embolism. When a patient's D-dimer rise combined with severe chest pain, the physician should be wary of pulmonary embolism, myocardial infarction, aortic dissection, and other emergencies, and should also take into account serious infections, tumors, and other diseases. Diagnosis needs further related examination. Chest CT scan has guidance function, and when the chest CT scan suggests the occupying lesion, the pathology examination is the key to identify the benign tumor.
-
Detection of carcinoembryonic Antigen (CEA) in pleural effusion has good clinical application value in differentiating benign and malignant pleural effusion, but sometimes CEA provides limited help. We report a case of a patient with left lung neoplasms combined with bilateral pleural effusion with increased CEA in the pleural effusion whose thoracoscopy pleural biopsy pathology was negative, mimicking lung carcinoma and ultimately confirmed as pulmonary sarcomatoid carcinoma by CT-guided percutaneous lung biopsy. ⋯ Elevated pleural effusion CEA is not a specific index of lung cancer. CT-guided percutaneous lung biopsy is appropriate for patients presenting with pleural diseases with lung neoplasms, especially when thoracoscopy pleural biopsy result was negative.
-
A high percentage of the critically ill polytrauma patients develop acute kidney injury (AKI) secondary to trauma and are therefore prone to high morbidity and mortality rates. One of the main objectives in these cases is the fast detection of the condition and continuous rigorous monitoring of the patients. Currently the panel of biomarkers available for monitoring and for the prognosis of AKI is limited. Numerous studies have proven the importance of microRNAs in this field. In this actualization paper we wish to summarize the most relevant microRNAs that can be used as biomarkers for patients with AKI. ⋯ The expression of microRNAs can be successfully used in the future as a non-invasive method for the evaluation and monitoring of AKI patients.
-
Review Meta Analysis
Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
microRNAs are widely involved in a variety of life processes and considered as potential biomarkers of tumor prognosis. A growing number of studies have documented that miRNAs were associated with outcome in NSCLC patients and can act as a prognostic marker. However, existing studies concerning the relationship between miRNAs and outcome in NSCLC patients were contentious and dispersive. Therefore, a systematic metaanalysis to explore the prognostic value of miRNAs on NSCLC patients is urgently needed. ⋯ Our meta-analysis provided the evidence that miR-21, miR-200c, miR-125b, miR-148b, miR-365, miR-124, miR-32, miR-146a, and miR-375 can act as prognostic biomarkers in NSCLC.
-
Review Meta Analysis
Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
microRNAs are widely involved in a variety of life processes and considered as potential biomarkers of tumor prognosis. A growing number of studies have documented that miRNAs were associated with outcome in NSCLC patients and can act as a prognostic marker. However, existing studies concerning the relationship between miRNAs and outcome in NSCLC patients were contentious and dispersive. Therefore, a systematic metaanalysis to explore the prognostic value of miRNAs on NSCLC patients is urgently needed. ⋯ Our meta-analysis provided the evidence that miR-21, miR-200c, miR-125b, miR-148b, miR-365, miR-124, miR-32, miR-146a, and miR-375 can act as prognostic biomarkers in NSCLC.